New Weight Loss Pill Shows Promise in Trials
A new oral weight loss pill, orforglipron, is making headlines as it shows encouraging results in clinical trials, potentially offering a simpler alternative to injectable GLP-1 medications like Ozempic and Wegovy.
Manufactured by Eli Lilly, orforglipron has been reported to lead to “significant weight loss” and improvements in heart health metrics. This was highlighted in the recent phase 3 ATTAIN-1 trial published in the New England Journal of Medicine, which involved adults facing weight-related health issues but who did not have diabetes.
During the study, participants received treatment for 72 weeks with varying doses of the medication (6 mg, 12 mg, and 36 mg). The results revealed that the highest dose allowed users to shed an average of 27.3 pounds. Notably, nearly 60% of the participants experienced a weight drop of 10% or more, while close to 40% lost at least 15% of their body weight.
Among the 1,127 participants who started the trial with pre-diabetes, a remarkable 91% reached near-normal blood sugar levels compared to just 42% of those receiving a placebo. The drug also demonstrated significant reductions in various cardiovascular risk factors linked to obesity, including cholesterol levels and blood pressure.
Dr. Sean Wharton of the Wharton Medical Clinic, who led the research, emphasized that obesity is a serious global health issue that requires straightforward and effective treatment options. He stated that orforglipron’s results are promising and suggest it could serve as a first-choice therapy in primary care settings.
Eli Lilly is now looking to obtain official approval for orforglipron as a weight loss treatment, with hopes that it could be cleared as early as 2026. The company also plans to seek approval for its use in addressing type 2 diabetes. Some analysts even indicate that the FDA may expedite the review process.
Dr. Sue Decotiis, a medical weight loss expert based in New York, has welcomed the development of this new pill. She noted that it could offer a more affordable option for consumers, although she cautioned that the weight loss results, while impressive, may not match those achieved with injectables like Ozempic and Mounjaro.
Decotiis also mentioned that since orforglipron is an oral medication, it may lead to better patient compliance. However, she expressed some concerns about its safety profile compared to peptide-based options, noting potential long-term effects that are still unknown.
This new pill’s advancements may pave the way for more oral weight loss treatments in the future, giving hope to those struggling with obesity and related health issues.
